ReviewAntioxidants & redox signaling2011
Anticancer activity of metal complexes: involvement of redox processes.
Review in Antioxidants & redox signaling, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
139 citing papers in PubMed, 530 citations in OpenAlex.
- Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients.Metallomics : integrated biometal science · 2013Trial
- Metal coordination at biological interfaces: Mechanisms, therapeutics, and translation.Materials today. Bio · 2026Review
- Bidentate Metal-Binding Motifs in US FDA Approved Small Molecule Drugs.Journal of medicinal chemistry · 2026Review
- Ni(II) Complexes with Mixed Ligands, Reduced NInternational journal of molecular sciences · 2026Article
- Metal complexes in medicine: structural scaffoldsChemical science · 2026Review
- Manganese-Templated Nontrivial Structures for MRI and Therapy.Journal of the American Chemical Society · 2026Article
- In Vitro and In Vivo Effects of a Copper(II)-Hydrazone Complex Against Human Osteosarcoma.Pharmaceutics · 2026Article
- Metal-based triazoles as a medical marvel of the modern era: a comprehensive review.RSC advances · 2026Review
- Heteroleptic Metal Complexes of 4-(2-Pyridylazo)resorcinol and 1,10-Phenanthroline: Synthesis, Comprehensive Characterization, Electrochemical and Antioxidant Properties, and Computational Investigations.Bioinorganic chemistry and applications · 2026Article
- Development of novel Copper(II)-hydrazone complexes for targeting the inhibition of human osteosarcoma growth.Frontiers in chemistry · 2026Article
- ADMET Profiling of the Metallodrugs: A Comparative Review of Platinum, Palladium, Gold, Ruthenium, Copper, and Zinc Anticancer Complexes.Bioinorganic chemistry and applications · 2026Review
- Review of the Most Important Research Trends in Potential Chemotherapeutics Based on Coordination Compounds of Ruthenium, Rhodium and Iridium.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Significance of Nano Transition Metal Complexes as Anticancer and Antibacterial Therapeutic Agents.International journal of molecular sciences · 2025Article
- Chitosan/Bioactive Glass Microparticles Enriched with Therapeutic Metal Ions for Bone Tissue Engineering.ACS applied bio materials · 2025Article
- Tumor Niche Influences the Activity and Delivery of Anticancer Drugs: Pharmacology Meets Chemistry.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Insights into the Silver Camphorimine Complexes Interactions with DNA Based on Cyclic Voltammetry and Docking Studies.Molecules (Basel, Switzerland) · 2025Article
- Article
- Structural and biomedical investigations of novel ruthenium schiff base complexes.Scientific reports · 2025Article
- Pt(IV) Complexes as Anticancer Drugs and Their Relationship with Oxidative Stress.Biomedicines · 2025Review
- Metal-based immunogenic cell death inducers for cancer immunotherapy.Chemical science · 2025Review
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Cells require tight regulation of the intracellular redox balance and consequently of reactive oxygen species for proper redox signaling and maintenance of metal (e.g., of iron and copper) homeostasis. In several diseases, including cancer, this balance is disturbed. Therefore, anticancer drugs targeting the redox systems, for example, glutathione and thioredoxin, have entered focus of interest. Anticancer metal complexes (platinum, gold, arsenic, ruthenium, rhodium, copper, vanadium, cobalt, manganese, gadolinium, and molybdenum) have been shown to strongly interact with or even disturb cellular redox homeostasis. In this context, especially the hypothesis of "activation by reduction" as well as the "hard and soft acids and bases" theory with respect to coordination of metal ions to cellular ligands represent important concepts to understand the molecular modes of action of anticancer metal drugs. The aim of this review is to highlight specific interactions of metal-based anticancer drugs with the cellular redox homeostasis and to explain this behavior by considering chemical properties of the respective anticancer metal complexes currently either in (pre)clinical development or in daily clinical routine in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.